Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy

Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy

Background: Despite advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC), primary and secondary resistance to current therapies remains. Elevated circulating sphingolipids are associated with poor outcomes in patients with mCRPC, including therapeutic resistance and s...

Full description

Saved in:
Bibliographic Details
Main Authors: Rhiannon Mellor, Luke Ardolino, Tahlia Scheinberg, Michael Fitzpatrick, Hui-Ming Lin, Paul Bonnitcha, David Sullivan, Peter J. Meikle, Martin R. Stockler, Tania Moujaber, Anthony Joshua, Lisa Horvath
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241307814
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17588359241307814

Similar Items